Dynamic Technology Lab Private Ltd Makes New Investment in CVS Health Co. (NYSE:CVS)

Dynamic Technology Lab Private Ltd bought a new stake in CVS Health Co. (NYSE:CVS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 24,742 shares of the pharmacy operator's stock, valued at approximately $1,111,000.

Other large investors have also made changes to their positions in the company. EagleClaw Capital Managment LLC raised its holdings in CVS Health by 3.4% in the 4th quarter. EagleClaw Capital Managment LLC now owns 6,135 shares of the pharmacy operator's stock worth $275,000 after purchasing an additional 200 shares during the period. Manchester Capital Management LLC lifted its stake in shares of CVS Health by 4.8% during the 4th quarter. Manchester Capital Management LLC now owns 4,457 shares of the pharmacy operator's stock valued at $200,000 after buying an additional 204 shares in the last quarter. Angeles Investment Advisors LLC increased its stake in CVS Health by 3.7% in the 4th quarter. Angeles Investment Advisors LLC now owns 5,706 shares of the pharmacy operator's stock worth $256,000 after buying an additional 204 shares in the last quarter. Rogco LP lifted its position in shares of CVS Health by 3.2% in the fourth quarter. Rogco LP now owns 6,752 shares of the pharmacy operator's stock valued at $303,000 after acquiring an additional 210 shares in the last quarter. Finally, Cozad Asset Management Inc. boosted its stake in shares of CVS Health by 3.7% in the fourth quarter. Cozad Asset Management Inc. now owns 6,532 shares of the pharmacy operator's stock worth $293,000 after acquiring an additional 233 shares during the period. 80.66% of the stock is currently owned by institutional investors.

CVS Health Stock Performance

Shares of NYSE:CVS traded down $0.08 during trading on Friday, hitting $68.89. 2,443,772 shares of the stock traded hands, compared to its average volume of 11,705,977. The company has a fifty day moving average price of $64.84 and a two-hundred day moving average price of $58.43. CVS Health Co. has a 52-week low of $43.56 and a 52-week high of $71.66. The company has a market cap of $86.85 billion, a price-to-earnings ratio of 18.81, a P/E/G ratio of 0.98 and a beta of 0.57. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. As a group, equities analysts predict that CVS Health Co. will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd will be paid a dividend of $0.665 per share. The ex-dividend date is Tuesday, April 22nd. This represents a $2.66 annualized dividend and a yield of 3.86%. CVS Health's dividend payout ratio (DPR) is currently 72.68%.

Insider Buying and Selling at CVS Health

In related news, SVP James David Clark sold 7,513 shares of CVS Health stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the transaction, the senior vice president now owns 8,394 shares in the company, valued at approximately $556,941.90. This trade represents a 47.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Michael F. Mahoney purchased 30,000 shares of CVS Health stock in a transaction dated Tuesday, February 18th. The shares were bought at an average price of $66.70 per share, for a total transaction of $2,001,000.00. Following the acquisition, the director now owns 39,356 shares in the company, valued at approximately $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.24% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

CVS has been the subject of a number of research analyst reports. Wolfe Research increased their price objective on shares of CVS Health from 67.00 to 70.00 and gave the company an "overweight" rating in a report on Tuesday, February 11th. Wells Fargo & Company lifted their price target on shares of CVS Health from $68.00 to $73.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. Evercore ISI lifted their price objective on CVS Health from $60.00 to $65.00 and gave the stock an "outperform" rating in a research note on Monday, January 27th. Argus set a $77.00 price target on shares of CVS Health in a research note on Tuesday, February 18th. Finally, StockNews.com raised shares of CVS Health from a "sell" rating to a "hold" rating in a report on Thursday, February 13th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $71.28.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.